Ralf Ludwig: When a Promising Biomarker Falls Short
Ralf Ludwig, Director of the Lübeck Institute of Experimental Dermatology at the University of Lübeck, shared a post on LinkedIn, about a recent article by Ahmad Alsaber et al., published in Frontiers in Medicine, adding:
“A paper that went looking for a biomarker, found nothing, and got published on the strength of how well it looked.
That’s how it should work.
The third paper in our Research Topic is a null result – and it earns its place precisely because it is one.
The hypothesis was reasonable: in rheumatoid arthritis, inflammation reshapes lipid metabolism, so perhaps the triglyceride-to-HDL ratio could serve as a cheap surrogate for disease activity.
Tidy idea.
Using 1,212 adults from the Kuwait Registry for Rheumatic Diseases – a Gulf population where this question is barely studied – the authors tested it properly.
It didn’t hold.
TG/HDL showed no independent association with disease activity (DAS28).
Nor did LDL, HDL, or triglycerides alone.
The finding survived every stress test the authors threw at it: a higher activity threshold, continuous scoring, expanded confounder adjustment, subgroups by sex and obesity.
Reliably, robustly null.
Which is the point.
A convenient surrogate that doesn’t work is worth knowing before someone builds a clinic pathway on it – and the authors are admirably plain about their own limitations.
Negative findings from under-represented populations are exactly the kind of honest science that tends to die in a file drawer.
This one didn’t.
Paper 3 of seven now published in the collection.
Congratulations to Ahmad Alsaber and colleagues …!
Submit your study․”
Title: Lipid parameters and disease activity in rheumatoid arthritis: a cross-sectional analysis of the Kuwait registry for rheumatic diseases (KRRD)
Authors: Fatima Ali, Ghaydaa Aldabie, Ahmad Alsaber
Stay updated with Hemostasis Today.
-
Aug 22, 2026, 11:14Lei Yu: New Guidance for Acute Pulmonary Embolism in 2026
-
Aug 22, 2026, 11:01Neeraj Songara: Shelf-Stable Synthetic Blood – The Future of Emergency Transfusion?
-
Aug 22, 2026, 10:41Mike R.։ VTE Thrombectomy – Defining What Success Really Means
-
Aug 22, 2026, 10:28Steven Meier: What Happens During PRP Therapy?
-
Aug 22, 2026, 09:33Mary Cushman: What Causes PE to Happen in People with DVT?
-
Aug 22, 2026, 07:45Ziad Hijazi: Refining Risk Assessment in Atrial Fibrillation Without Oral Anticoagulation
-
Aug 22, 2026, 07:35Archil Jaliashvili: The Real Battle Is Not About Blood Volume — It Is About Oxygen
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One